Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Linzagolix

Catalog No: 20266
CAS Number: 935283-04-8
Purity: ≧98.0%

Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. 

For research use only. We do not sell to patients.

Chemical Information

NameLinzagolix
Iupac Chemical Name3-{5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl}-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid
SynonymsLinzagolix ; OBE2109 ; OBE 2109 ; OBE-2109 ; KLH-2109 ; KLH 2109 ; KLH2109 ;
Molecular FormulaC22H15F3N2O7S
Molecular Weight508.42
SmileO=C(C1=C(C(N2C3=CC(OCC4=C(OC)C=CC(F)=C4F)=C(OC)C=C3F)=O)C(NC2=O)=CS1)O
InChiKeyBMAAMIIYNNPHAB-UHFFFAOYSA-N
InChiInChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
CAS Number935283-04-8
Related CAS935283-04-8 (free) ; 1321816-57-2 (choline)

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
BulkEnquiryEnquiryEnquiry
Request Bulk Quote Download MSDS Tel : +86-27-65522453   Email : sales@sun-shinechem.com
FormulationOff-white solid
Purity≧98.0%
StorageDry, dark and at 0-4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
SolubilitySoluble in DMSO
HandlingRefer to MSDS operation
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
HS Code2934200090
Coming soon.
TargetsGnRH receptor antagonist
Mechanism
Cell study
Animal study
Clinical study

1: Borini A, Coticchio G. Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? Fertil Steril. 2020 Sep;114(3):517-518. doi: 10.1016/j.fertnstert.2020.06.003. Epub 2020 Aug 3. PMID: 32762949.

2: Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020 Sep;114(3):640-645. doi: 10.1016/j.fertnstert.2020.04.017. Epub 2020 Jun 2. PMID: 32507315.

3: Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44-55. doi: 10.1016/j.fertnstert.2020.02.114. Epub 2020 Jun 4. PMID: 32505383.

4: Pohl O, Marchand L, Bell D, Gotteland JP. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020 Apr;27(4):988-995. doi: 10.1007/s43032-020-00172-z. Epub 2020 Feb 25. PMID: 32100275.


Chemical Structure

20266 - Linzagolix | CAS 935283-04-8

Quick Order

Change